Welcome to LookChem.com Sign In|Join Free

CAS

  • or

329940-36-5

Post Buying Request

329940-36-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

329940-36-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 329940-36-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,9,9,4 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 329940-36:
(8*3)+(7*2)+(6*9)+(5*9)+(4*4)+(3*0)+(2*3)+(1*6)=165
165 % 10 = 5
So 329940-36-5 is a valid CAS Registry Number.

329940-36-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-methyl-3-nitro-4-methylbenzamide

1.2 Other means of identification

Product number -
Other names 4-Methyl-3-nitro-benzoesaeure-methylamid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:329940-36-5 SDS

329940-36-5Relevant articles and documents

The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4- oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases

Brown, Dearg S.,Cumming, John G.,Bethel, Paul,Finlayson, Jonathan,Gerhardt, Stefan,Nash, Ian,Pauptit, Richard A.,Pike, Kurt G.,Reid, Alan,Snelson, Wendy,Swallow, Steve,Thompson, Caroline

scheme or table, p. 3879 - 3883 (2012/07/03)

A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clinical candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin- 3(4H)-yl]benzamide (AZD6703). Optimisation was guided by understanding of the binding modes from X-ray crystallographic studies which showed a switch from DFG 'out' to DFG 'in' as the inhibitor size was reduced to improve overall properties.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 329940-36-5